Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Convertible Debt (2021 - 2025)

Heron Therapeutics (HRTX) has disclosed Convertible Debt for 6 consecutive years, with $32.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Convertible Debt fell 78.13% year-over-year to $32.7 million, compared with a TTM value of $32.7 million through Dec 2025, down 78.13%, and an annual FY2025 reading of $32.7 million, down 78.13% over the prior year.
  • Convertible Debt was $32.7 million for Q4 2025 at Heron Therapeutics, up from $32.2 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $149.8 million in Q1 2025 and bottomed at $32.2 million in Q3 2025.
  • Average Convertible Debt over 5 years is $136.4 million, with a median of $149.3 million recorded in 2022.
  • Peak annual rise in Convertible Debt hit 0.14% in 2025, while the deepest fall reached 78.5% in 2025.
  • Year by year, Convertible Debt stood at $149.1 million in 2021, then increased by 0.14% to $149.3 million in 2022, then grew by 0.14% to $149.5 million in 2023, then increased by 0.14% to $149.7 million in 2024, then tumbled by 78.13% to $32.7 million in 2025.
  • Business Quant data shows Convertible Debt for HRTX at $32.7 million in Q4 2025, $32.2 million in Q3 2025, and $149.8 million in Q1 2025.